HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

New Italian Pricing Decree To Drive R&D Transparency

Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.

Europe Italy

Italy: Added Benefit Will Be Key To Reimbursement

A draft decree in Italy aims to put added therapeutic value at the centre of reimbursement decisions.

Europe Italy

New Tool To Help Evaluate Quality of RWD

A new tool from the European Network For Health Technology Assessment to evaluate the quality of registries is now being piloted.

Europe Health Technology Assessment

Austria Works On Method To Improve Price Transparency

Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.

Europe Austria

Scottish HTA Reverses No For Yescarta

The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.

United Kingdom Cancer

UK Labour Government Would De-Link Innovation & Drug Pricing

The Labour Party says it would overhaul the system for pricing medicines in the UK by de-linking innovation and price incentives if it gets into office at the next general election.

Europe United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register